Earnings History Data for Protagonist Therapeutics (PTGX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
27-02-2024	PM		PTGX	Protagonist Therapeutics	1,643	0.44	-0.16	0.00	Protagonist GAAP EPS of $0.44 [2/28/2024 1:28 AM]	30.40	0.81 (2.74%)	29.92	0.33 (1.12%)	13.72 - 31.40	469,357	470,000	63,306
Protagonist GAAP EPS of $0.44 [2/28/2024 1:28 AM]
15-03-2023	AH		PTGX	Protagonist Therapeutics	1,249	-0.69	-0.67	0.00	Protagonist GAAP EPS of -$0.69 misses by $0.10 [3/15/2023 4:46 PM]	23.08	-0.97 (-4.03%)	24.00	-0.05 (-0.21%)	6.91 - 27.41	1,715,748	4,400,000	424
Protagonist GAAP EPS of -$0.69 misses by $0.10 [3/15/2023 4:46 PM]
08-11-2022	AH	4:05 PM ET (Nov 8)	PTGX	Protagonist Therapeutics	387.00	-0.64	-0.94	0.00	Protagonist GAAP EPS of -$0.64 beats by $0.23 [11/8/2022 5:44 PM]	7.74	0.0 (0.00%)	7.71	-0.03 (-0.39%)	6.91 - 38.11	564,739	640,000	1,958
Protagonist GAAP EPS of -$0.64 beats by $0.23 [11/8/2022 5:44 PM] Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update [Nov-08-22 04:05PM]
04-05-2022	AH	4:05 PM ET (May 4)	PTGX	Protagonist Therapeutics, Inc.	441.34	-0.43	-0.67	-0.54	Protagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65M [5/4/2022 5:41 PM]	9.71	-0.10 (-1.07%)	9.88	0.06 (0.61%)	8.63 - 50.54	982,278	2,210,000	6,229
Protagonist GAAP EPS of -$0.43 beats by $0.20, revenue of $25.7M beats by $8.65M [5/4/2022 5:41 PM] Shareholders in Protagonist Therapeutics (NASDAQ:PTGX) are in the red if they invested a year ago [May-04-22 01:29PM] Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update [May-04-22 04:05PM] Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates [May-04-22 06:35PM]
28-02-2022	AH		PTGX	Protagonist Therapeutics	1,157	-0.77	-0.79	0.00	Protagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62M [2/28/2022 5:17 PM]	26.29	2.01 (8.28%)	24.28	0.0 (0.00%)	12.80 - 50.54	643,968	1,010,000	18,988
Protagonist GAAP EPS of -$0.77 beats by $0.02, revenue of $8.62M beats by $4.62M [2/28/2022 5:17 PM] Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update [Feb-28-22 04:05PM] Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates [Feb-28-22 06:15PM]
04-05-2021	AH		PTGX	Protagonist Therapeutics, Inc.	1,272	-0.54	-0.57	0.00	Protagonist EPS beats by $0.03, beats on revenue [5/4/2021 5:10 PM]	29.10	-0.25 (-0.85%)	29.10	0.0 (0.00%)	7.61 - 32.10	200,214	270,000	1,036
Protagonist EPS beats by $0.03, beats on revenue [5/4/2021 5:10 PM] Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update [May-04-21 04:01PM] Protagonist Therapeutics Reports Granting of Inducement Award [May-03-21 05:47PM] Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates [May-04-21 06:20PM]
10-03-2021	AH	4:55 PM ET (Mar 10)	PTGX	Protagonist Therapeutics, Inc.	1,250	-0.48	-0.48	-0.63	Protagonist EPS in-line, beats on revenue [3/10/2021 4:28 PM]	30.74	0.91 (3.05%)	29.83	0.0 (0.00%)	5.30 - 31.58	411,382	450,220	4,732
Protagonist EPS in-line, beats on revenue [3/10/2021 4:28 PM] Protagonist Therapeutics, Inc. to Host Earnings Call [Mar-10-21 01:30PM] Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates [Mar-10-21 05:55PM] Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update [Mar-10-21 04:01PM]
04-11-2020	AH	4:00 PM ET (Nov 4)	PTGX	Protagonist Therapeutics, Inc.	717.75	-0.21	-0.61	-0.61	Protagonist EPS beats by $0.40, beats on revenue [11/4/2020 5:06 PM]	23.04	1.82 (8.58%)	22.40	1.18 (5.56%)	4.47 - 23.25	263,710	260,523	7,794